Regulation of muscle oxidative phenotype by hypoxia in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Heart Failure (CHF)
Completed
- Conditions
- COPD, chronic heart failurehypoxemia, skeletal muscle dysfunction
- Registration Number
- NL-OMON26311
- Lead Sponsor
- Maastricht University (transnationale Universiteit Limburg)
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
1. COPD patients: COPD according to GOLD criteria.
2. CHF patients: diagnosis heart failure with an ejection fraction <40% determined by echocardiography;
Exclusion Criteria
COPD patients:
malignancy, cardiac failure, distal arteriopathy, recent surgery, severe endocrine, hepatic or renal disorders, oxygen therapy and recent participation in a revalidation program (previous 6 months).
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Main outcome parameters are the expression levels of HIF-1á, PGC-1 and PPARs (before and after exercise), which will be measured at protein and mRNA level by western blotting and PCR respectively;<br /><br>2. Also, markers of hypoxia such as vascular endothelial growth factor (VEGF), carbonic anhydrase-9 (CA-9) and heme oxygenase-1 (HO-1) will be investigated using real time PCR;<br /><br>3. Beside this, metabolic enzyme activities (citrate synthase, â-hydroxyacyl-CoA dehydrogenase, phosphofructokinase) and muscle fiber type proportions will be determined to assess muscle oxidative phenotype;<br /><br>4. Main outcomes in the adipose tissue biopsies comprise of adipocyte size, gene expression levels of inflammatory and hypoxia-related genes and adipose tissue macrophage infiltration.
- Secondary Outcome Measures
Name Time Method Secondary outcome parameters are skeletal muscle function and exercise capacity.